Rhythm制药 RYTM 深 沪
等待开盘 07-02 09:30:00 美东时间
110.41
-0.620
-0.56%
华盛通- 最 高114.585
- 今 开111.07
- 成交量 99.92万股
- 最 低 110.01
- 昨 收 111.03
- 总市值 75.73亿
- 52周最高 122.20
- 市盈率 静 --
- 换手率 1.46%
- 52周最低 74.50
- 委 比 46.19%
- 总股本 6859.36万
- 历史最高 122.20
- 量 比 0.78
- 振 幅 4.12%
- 历史最低 3.04
- 每 手 1
- 风险率 10.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅117.92%！摩根大通上调Camp4 Therapeutics目标价至9美元，维持"超配"评级
今日重点评级关注：摩根大通：上调Camp4 Therapeutics评级至"超配"，目标价从5美元升至9美元；Canaccord Genuity：维持Rhythm制药"买入"评级，目标价从143美元升至151美元
06-17 11:32
美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
Why Is Rhythm Pharma Stock Jumping Today?
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) stock is trading higher on Monday after the company reported preliminary results from an ongoing Phase 2 study evaluating setmelanotide in patients with Prader-Willi syndrome (PWS). The six-month data shared on Saturday showed improvements in body mass index...
06-16 00:51
Rhythm Pharmaceuticals To Present Interim Phase 2 Setmelanotide Data In Prader-Willi Syndrome On June 13 At 9:00 a.m. ET
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. ...
06-13 04:02
Medtronic's Cardiovascular Boom Offsets Margin Pressure
Medtronic (MDT) stock jumps after beating Q4 revenue expectations, driven by strong growth in cardiovascular and diabetes tech.
06-03 23:03
Rhythm Pharmaceuticals Announces Publication Of An Evidence-Based, Consensus-Driven Diagnostic Algorithm For Bardet-Biedl Syndrome
"Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria," was published in the peer-reviewed American Journal of Medical Genetics.This simplified and practical diagnostic
05-28 20:06
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
财报速睇 | Rhythm制药 2026财年Q1营收0.60亿美元，同比增长83.8%；归母净利润亏损0.57亿美元，同比亏损扩大11.7%
华盛资讯5月6日讯，Rhythm制药公布2026财年Q1业绩，公司Q1营收0.60亿美元，同比增长83.8%，归母净利润亏损0.57亿美元，同比亏损扩大11.7%。
05-06 05:49
Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call
On Tuesday, Rhythm Pharmaceuticals (NASDAQ:RYTM) discussed first-quarter financ...
05-05 21:09
